The Polycystic Ovary Syndrome (PCOS) Treatment Market Size is valued at 3.71 Billion in 2023 and is predicted to reach 5.76 Billion by the year 2031 at a 5.75% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The polycystic ovarian syndrome treatment market experienced growth due to a rise in PCOS prevalence and an increase in the patient population.
- Research and development in PCOS also assisted in the growth of the market.
- The overall market was dominated by the Asia Pacific region, which accounted for a significant global revenue share in 2023.
- The key challenge for the Polycystic Ovary Syndrome (PCOS) Treatment Market is the lack of specific treatment options and approved therapeutics for PCOS.
Women of childbearing age frequently have polycystic ovarian syndrome (PCOS), a hormonal disorder. Menstrual cycles that are irregular or prolonged, as well as excessive levels of male hormones, might be caused by PCOS. There is no known treatment for PCOS, but several medications control its symptoms and menstrual cycle. An increase in PCOS prevalence, an increase in patient population knowledge, and an increase in the use of combination therapy are the major factors driving the growth of the polycystic ovarian syndrome treatment market. Advances in PCOS screening technology, the rise in demand for PCOS medications, and the accessibility of PCOS treatment also impact the market's expansion. However, it is anticipated that market growth will be constrained by the lack of approved treatments and PCOS's uncertain pathophysiology and etiology.
Additionally, during the projected period, the unrealized potential of developing economies presents lucrative market growth opportunities. As the prevalence of polycystic ovarian syndrome (PCOS) rises, so is the need for treatment. However, the absence of specialized treatment for PCOS disease is anticipated to impede market expansion.
Competitive Landscape
Some major key players in the Polycystic Ovary Syndrome (PCOS) Treatment Market:
- Novartis AG,
- Sanofi,
- Teva Pharmaceutical Industries Limited,
- Merck & Co., Inc. (Merck group),
- AstraZeneca plc.,
- Bayer AG.
- Abbott,
- Pfizer, Inc,
- Bristol-Myer Squibb Company,
- Ferring Pharmaceuticals, Inc.,
- Johnson and Johnson,
- Mylan N.V.,
- Allergan plc.,
- GlaxoSmithKline,
- Lupin Pharmaceuticals,
- AbbVie,
- Takeda,
- BIOCAD Global,
- Blairex Laboratories Inc
- Agile Therapeutics
Market Segmentation:
The polycystic ovary syndrome (PCOS) treatment market is segmented on the drug class and distribution channel. Based on drug class, the market is segmented into oral contraceptives, insulin sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. Based on distribution channel, polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics.
Based On Drug Class, The Insulin Sensitizing Agents Segment Is Accounted As A Major Contributor To The Polycystic Ovary Syndrome (PCOS) Treatment Market.
Based on drug class, the market is segmented into oral contraceptives, insulin-sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. The insulin-sensitizing agent's category grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Numerous items are offered for sale, including Glucophage X.R. (Metformin) and other items that contain Troglitazone, Rosiglitazone, and Pioglitazone. Metabolic dysfunction in PCOS may cause an overproduction of androgen, impacting insulin secretion and raising the risk of diabetes. As a result, insulin-sensitizing drugs are crucial for therapeutics because they balance hormone levels, lower insulin levels, and reduce ovarian androgen production.
The E-Commerce Retailing Segment Witnessed Growth At A Rapid Rate.
Based on the distribution channel, the polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics. The e-commerce category is anticipated to grow significantly over the forecast period because more people prefer buying medicines online over traditional means, more people are aware of online sources, and more people are using the internet.
The Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Holds A Significant Revenue Share In The Region.
The Asia Pacific polycystic ovary syndrome (PCOS) treatment market is expected to register the highest market share in revenue shortly. The market will expand due to the rising acceptance of products for treating polycystic ovarian syndrome and increased knowledge of the treatment. The development of the R&D sector, the expansion of the target population, the growth of healthcare reforms, and technological developments in the healthcare industry all contribute to the market's expansion. Additionally, North America is anticipated to expand at a significant rate over the course of the forecast period. Factors like the increased focus of major manufacturers on growing their geographic presence in developing Asia-Pacific nations to seize a large population base, high growth opportunities in the market, and high disposable incomes are also anticipated to propel the growth of the market in the region.
Recent Developments:
- In June 2022, Bayer unveiled its new Research and Innovation Center at Kendall Square in the United States, further expanding its position in a highly advanced hub for pharmaceutical research and development.
Polycystic Ovary Syndrome (PCOS) Treatment Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3.71Billion |
|
Revenue Forecast In 2031 |
USD 5.76 Billion |
|
Growth Rate CAGR |
CAGR of 5.75% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug Class, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Novartis AG, Sanofi, Teva Pharmaceutical Industries Limited, Merck & Co., Inc. (Merck group), AstraZeneca plc., Bayer AG. Abbott, Pfizer, Inc, Bristol-Myer Squibb Company, Ferring Pharmaceuticals, Inc., Johnson and Johnson, Mylan N.V., Allergan plc., GlaxoSmithKline, Lupin Pharmaceuticals, AbbVie, Takeda, BIOCAD Global, Blairex Laboratories Inc and Agile Therapeutics |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
